Patents by Inventor Katherine N. Keenan

Katherine N. Keenan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Prodrug derivatives of protein kinase C modulators
    Patent number: 11370743
    Abstract: Embodiments of prodrugs of PKC modulators that show efficacy coupled with low levels of toxicity and improved stability are provided. The prodrug compounds are useful in academic research (animal studies), as candidates for preclinical research, and as therapeutic agents. By taking advantage of a pharmacophore-based strategy, this design strategy provides access to prodrugs of PKC modulators of diverse scaffolds including tigliane diterpenes, ingenane diterpenes, daphnane diterpene orthoesters, diacylglycerols, and bryostatins, and analogs thereof. In particular, embodiments of the prodrug ingenane esters having substitutions at C20 and their use as therapeutic agents are provided.
    Type: Grant
    Filed: May 10, 2018
    Date of Patent: June 28, 2022
    Assignee: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: Paul A. Wender, Katherine N. Keenan, Nancy Lynn Benner, Jack Leider Sloane, Xiaoyu Zang
  • PRODRUG DERIVATIVES OF PROTEIN KINASE C MODULATORS
    Publication number: 20210002203
    Abstract: Embodiments of prodrugs of PKC modulators that show efficacy coupled with low levels of toxicity and improved stability are provided. The prodrug compounds are useful in academic research (animal studies), as candidates for preclinical research, and as therapeutic agents. By taking advantage of a pharmacophore-based strategy, this design strategy provides access to prodrugs of PKC modulators of diverse scaffolds including tigliane diterpenes, ingenane diterpenes, daphnane diterpene orthoesters, diacylglycerols, and bryostatins, and analogs thereof. In particular, embodiments of the prodrug ingenane esters having substitutions at C20 and their use as therapeutic agents are provided.
    Type: Application
    Filed: May 10, 2018
    Publication date: January 7, 2021
    Inventors: Paul A. Wender, Katherine N. Keenan, Nancy Lynn Benner, Jack Leider Sloane, Xiaoyu Zang